INT65135

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1995
Last Reported 2010
Negated 2
Speculated 0
Reported most in Abstract
Documents 17
Total Number 18
Disease Relevance 1.82
Pain Relevance 5.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C19) oxidoreductase activity (CYP2C19) endoplasmic reticulum (CYP2C19)
enzyme binding (CYP2C19)
Anatomy Link Frequency
liver 1
hair 1
saliva 1
CYP2C19 (Homo sapiens)
Pain Link Frequency Relevance Heat
methadone 35 99.96 Very High Very High Very High
antidepressant 11 99.92 Very High Very High Very High
beta blocker 1 99.76 Very High Very High Very High
Opioid 8 99.72 Very High Very High Very High
cINOD 4 98.92 Very High Very High Very High
Duloxetine 20 96.48 Very High Very High Very High
fluoxetine 24 95.60 Very High Very High Very High
opioid receptor 3 92.16 High High
Angina 1 89.28 High High
Central nervous system 13 81.84 Quite High
Disease Link Frequency Relevance Heat
Toxicity 5 94.88 High High
Disease 20 89.40 High High
Cv General 3 Under Development 1 89.28 High High
Anxiety Disorder 92 86.56 High High
Gastroesophageal Reflux Disease 65 79.44 Quite High
Hepatic Insufficiency 4 77.60 Quite High
Body Weight 1 68.40 Quite High
Fibromyalgia 200 66.68 Quite High
Injury 3 62.00 Quite High
INFLAMMATION 10 58.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Food and Drug Administration guidance for in vitro drug-drug interactions with CYP2C19.
CYP2C19 Binding (interactions) of
1) Confidence 0.48 Published 2008 Journal Drug Metab. Dispos. Section Abstract Doc Link 18048485 Disease Relevance 0 Pain Relevance 0.29
After normalization by its relative abundance in human liver microsomes, CYP2B6, CYP3A4, and CYP2C19 accounted for 57, 28, and 15% of the total intrinsic clearance of meperidine.
CYP2C19 Binding (accounted) of in liver
2) Confidence 0.36 Published 2004 Journal Drug Metab. Dispos. Section Abstract Doc Link 15319333 Disease Relevance 0 Pain Relevance 0.23
Investigations with recombinant CYP3A4 and CYP2C19 confirmed that the demethylation of tilidine occurs via these two CYPs.
CYP2C19 Binding (recombinant) of
3) Confidence 0.36 Published 2008 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 18516595 Disease Relevance 0 Pain Relevance 0.11
Important drug interactions may result from inhibition of hepatic CYP2C19 activity in extensive metabolisers or from the interaction of CYP2C19 substrates with other pathways in poor metabolisers.
CYP2C19 Binding (interaction) of
4) Confidence 0.36 Published 1995 Journal Clin Pharmacokinet Section Abstract Doc Link 8846622 Disease Relevance 0 Pain Relevance 0.10
Although the (S)-isomer exhibits a much lower affinity for CYP2C19 inactivation relative to the (R)-enantiomer, it exhibits a more rapid rate of inactivation.
CYP2C19 Binding (affinity) of
5) Confidence 0.36 Published 2009 Journal Drug Metab. Dispos. Section Abstract Doc Link 19144769 Disease Relevance 0 Pain Relevance 0.57
Clinically well-established polymorphic CYPs (i.e., CYP2C9, CYP2C19, and CYP2D6) were involved in the metabolism of approximately half of those drugs, including (in particular) NSAIDs metabolized mainly by CYP2C9, proton-pump inhibitors metabolized by CYP2C19, and beta blockers and several antipsychotics and antidepressants metabolized by CYP2D6.
CYP2C19 Binding (metabolized) of associated with antidepressant, beta blocker and cinod
6) Confidence 0.36 Published 2008 Journal Anal Bioanal Chem Section Abstract Doc Link 18695978 Disease Relevance 0 Pain Relevance 0.20
Determination of metabolic genotype revealed that the patient had a wild-type genotype for CYP2C9, CYP2C19, and CYP2D6.
CYP2C19 Binding (genotype) of
7) Confidence 0.35 Published 1997 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 9390115 Disease Relevance 0.25 Pain Relevance 0.09
In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.
CYP2C19 Binding (interaction) of associated with opioid
8) Confidence 0.35 Published 2008 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Title Doc Link 18516595 Disease Relevance 0 Pain Relevance 0.15
In vivo, drug-drug interactions of tilidine with CYP3A4 or CYP2C19 inhibitors are to be anticipated, whereas substrates of CYP2C19, ABCB1, or ABCG2 will presumably not be influenced by tilidine or nortilidine.
CYP2C19 Binding (interactions) of
9) Confidence 0.35 Published 2008 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 18516595 Disease Relevance 0 Pain Relevance 0.07
In contrast, enantiomer interactions were not stereoselective with CYP2C19 or CYP3A4.
CYP2C19 Binding (interactions) of
10) Confidence 0.34 Published 2007 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 17259447 Disease Relevance 0 Pain Relevance 1.17
Minor fractions were catalyzed by recombinant P450s CYP1A1, CYP2B6, CYP2C19, CYP2D6, and CYP2E1.
CYP2C19 Binding (recombinant) of
11) Confidence 0.34 Published 2009 Journal Drug Metab. Dispos. Section Abstract Doc Link 19204080 Disease Relevance 0.11 Pain Relevance 0.14
When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference.
CYP2C19 Binding (metabolized) of associated with methadone
12) Confidence 0.24 Published 2004 Journal Chirality Section Abstract Doc Link 14628297 Disease Relevance 0 Pain Relevance 1.13
Other advantages of genotyping over traditional TDM include, but are not limited to, the following: (i) it does not require the assumption of steady-state conditions (or patient compliance) for the interpretation of results; (ii) it can often be performed less invasively (with saliva, hair root or buccal swab samples); (iii) it can provide predictive value for multiple drugs [e.g. a number of cytochrome P450 (CYP) 2D6, CYP2C 19 or CYP2C9 substrates] rather than a single drug; (iv) it provides mechanistic, instead of merely descriptive, information; and (v) it is constant over an individual's lifetime (and not influenced by concurrent drug administration, alteration in hormonal levels or disease states).
CYP2C 19 Binding (number) of in hair associated with disease
13) Confidence 0.17 Published 2001 Journal Clin Pharmacokinet Section Abstract Doc Link 11735602 Disease Relevance 0.09 Pain Relevance 0
The interaction between milnacipran and the cytochrome P450 (CYP) isoenzymes is limited, with no interaction with CYP2D6 or CYP2C19 pathways and minimal interaction with CYP1A2, CYP2C19, CYP2D6 and CYP3A4.
CYP2C19 Neg (no) Binding (interaction) of
14) Confidence 0.08 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004654 Disease Relevance 0.27 Pain Relevance 0.21
The interaction between milnacipran and the cytochrome P450 (CYP) isoenzymes is limited, with no interaction with CYP2D6 or CYP2C19 pathways and minimal interaction with CYP1A2, CYP2C19, CYP2D6 and CYP3A4.
CYP2C19 Neg (no) Binding (interaction) of
15) Confidence 0.08 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004654 Disease Relevance 0.28 Pain Relevance 0.21
Other advantages of genotyping over traditional TDM include, but are not limited to, the following: (i) it does not require the assumption of steady-state conditions (or patient compliance) for the interpretation of results; (ii) it can often be performed less invasively (with saliva, hair root or buccal swab samples); (iii) it can provide predictive value for multiple drugs [e.g. a number of cytochrome P450 (CYP) 2D6, CYP2C 19 or CYP2C9 substrates] rather than a single drug; (iv) it provides mechanistic, instead of merely descriptive, information; and (v) it is constant over an individual's lifetime (and not influenced by concurrent drug administration, alteration in hormonal levels or disease states).
CYP2C 19 Binding (number) of in saliva associated with disease
16) Confidence 0.06 Published 2001 Journal Clin Pharmacokinet Section Abstract Doc Link 11735602 Disease Relevance 0.09 Pain Relevance 0
PPIs, mainly omeprazole, are metabolized to different degrees by the P450 hepatic enzyme system, specifically by the CYP2C19 and CYP3A4 enzymes.
CYP2C19 Binding (metabolized) of
17) Confidence 0.06 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963162 Disease Relevance 0.57 Pain Relevance 0.11
Citalopram and escitalopram are weak inhibitors of CYP450 isoenzymes and are less likely than other second-generation antidepressants to interact with coadministered medications.33 Clomipramine significantly inhibits CYP2C19.34
CYP2C19 Binding (interact) of associated with antidepressant
18) Confidence 0.03 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2877605 Disease Relevance 0.17 Pain Relevance 0.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox